+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Evidence for heterogeneity of the obstetric antiphospholipid syndrome: thrombosis can be critical for antiphospholipid-induced pregnancy loss

Evidence for heterogeneity of the obstetric antiphospholipid syndrome: thrombosis can be critical for antiphospholipid-induced pregnancy loss

Journal of Thrombosis and Haemostasis 9(10): 1937-1947

Antiphospholipid antibodies are associated with thrombosis and repeated pregnancy losses during the antiphospholipid syndrome. Several experimental findings indicate that purified antiphospholipid antibodies are directly responsible for inflammation-induced pregnancy losses, or for disruption of the annexin A5 shield at the trophoblastic interface. We previously showed that passive transfer of CIC15, a monoclonal antiphospholipid antibody binding to cardiolipin and annexin A5 that was isolated from a patient with primary antiphospholipid syndrome, induces fetal resorption in pregnant mice. To investigate the mechanisms of CIC15-induced pregnancy loss. We show that CIC15 induces fetal loss through a new mechanism that is probably related to procoagulant activity. The time course is different from those of previously described models, and histologic analysis shows that the placentas are devoid of any sign of inflammation but display some signs of thrombotic events. Despite these differences, the CIC15 and 'inflammatory' models share some similarities: lack of FcγRI/III dependency, and the efficacy of heparin in preventing fetal losses. However, this latter observation is here mostly attributable to anticoagulation rather than complement inhibition, because fondaparinux sodium and hirudin show similar efficiency. In vitro, CIC15 enhances cardiolipin-induced thrombin generation. Finally, using a combination of surface-sensitive methods, we show that, although it binds complexes of cardiolipin-annexin A5, CIC15 is not able to disrupt the two-dimensional ordered arrays of annexin A5. This human monoclonal antibody is responsible for pregnancy loss through a new mechanism involving thrombosis. This mechanism adds to the heterogeneity of the obstetric antiphospholipid syndrome.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 053094583

Download citation: RISBibTeXText

PMID: 21848640

DOI: 10.1111/j.1538-7836.2011.04475.x

Related references

Evidences for Heterogeneity of the Obstetrical Antiphospholipid Syndrome thrombosis can be Critical for Antiphospholipid-Induced Pregnancy Loss. 2011

IgG/IgM antiphospholipid antibodies present in the classification criteria for the antiphospholipid syndrome: a critical review of their association with thrombosis. Journal of Thrombosis and Haemostasis 14(8): 1530-1548, 2016

Treatment strategies and pregnancy outcomes in antiphospholipid syndrome patients with thrombosis and triple antiphospholipid positivity. A European multicentre retrospective study. Thrombosis and Haemostasis 112(4): 727-735, 2014

Management of thrombosis and pregnancy loss in the antiphospholipid syndrome. Lupus 7(Suppl. 2): S162-S165, 1998

Much more than thrombosis and pregnancy loss: the antiphospholipid syndrome as a 'systemic disease'. Best Practice and Research. Clinical Rheumatology 26(1): 79-90, 2012

Review : Management of thrombosis and pregnancy loss in the antiphospholipid syndrome. Lupus 7(2 Suppl.): S162-S165, 1998

Comparative study between obstetric antiphospholipid syndrome and obstetric morbidity related with antiphospholipid antibodies. Medicina Clinica 151(6): 215-222, 2018

Comparative incidence of a first thrombotic event in purely obstetric antiphospholipid syndrome with pregnancy loss: the NOH-APS observational study. Blood 119(11): 2624-2632, 2012

Recurrent thrombosis prevention with intravenous immunoglobulin and hydroxychloroquine during pregnancy in a patient with history of catastrophic antiphospholipid syndrome and pregnancy loss. Journal of Thrombosis and Thrombolysis 38(2): 196-200, 2014

Modulation of antiphospholipid antibodies-induced trophoblast damage by different drugs used to prevent pregnancy morbidity associated with antiphospholipid syndrome. American Journal of Reproductive Immunology 77(4):, 2017

Avidity of anti-beta2-glycoprotein I and thrombosis or pregnancy loss in patients with antiphospholipid syndrome. Annals of the new York Academy of Sciences 1051: 141-147, 2005

Complement activation as a mediator of antiphospholipid antibody induced pregnancy loss and thrombosis. Annals of the Rheumatic Diseases 61(Suppl. 2): Ii46-Ii50, 2002

Antiphospholipid antibodies other than lupus anticoagulant and anticardiolipin antibodies in women with recurrent pregnancy loss, fertile controls, and antiphospholipid syndrome. Obstetrics & Gynecology. 89(4): 549-555, 1997

Antiphospholipid sydrome--recurrent thrombosis and foetal loss due to antiphospholipid antibodies. Srpski Arhiv Za Celokupno Lekarstvo 122(5-6): 179-181, 1994

Tnf- Is a Critical Effector and a Target for Therapy in Antiphospholipid Antibody-Induced Pregnancy Loss. The Journal of Immunology 174(1): 485-490, 2005